Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Liabilities from Discontinued Operations (2023 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Liabilities from Discontinued Operations for 2 consecutive years, with 1190000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Liabilities from Discontinued Operations rose 70.49% to 1190000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 1190000.0, a 70.49% increase, with the full-year FY2024 number at 1190000.0, up 70.49% from a year prior.
  • Liabilities from Discontinued Operations was 1190000.0 for Q4 2024 at NovaBay Pharmaceuticals, up from 698000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 1190000.0 in Q4 2024 to a low of 698000.0 in Q4 2023.